KESIMPTA®▼(ofatumumab) downloadable resources
KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.1
This selection of resources is designed for healthcare professionals to support patients with relapsing forms of multiple sclerosis (RMS) throughout their KESIMPTA journey.
You can download these materials and share them with your healthcare team. There is a separate tab for resources which can be shared with patients. Please do not share this web page with patients; instead, please direct them to the patient portal where they can access these resources.
Reference
KESIMPTA (ofatumumab) Summary of Product Characteristics.
UK | January 2025 | 443408
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.